The National Academies of Science, Engineering and Medicine (NASEM) is scheduled to hold a webinar this month to discuss the science and health implications of CBD.
NASEM, which traces its origins back to legislation signed by President Abraham Lincoln in 1863, and which receives much of its funding from federal agencies, will host a one-hour forum to discuss “the current and emerging scientific knowledge on and the potential health implications” of the cannabis compound.
On October 17, the #NASEMFoodForum will host a webinar on the emerging science and potential health implications of CBD. Learn more and sign up here: https://t.co/z13Cq2gY6u pic.twitter.com/RSfMmpipGE
— National Academy of Medicine (@theNAMedicine) September 30, 2019
“Speakers will address the challenges to defining CBD, the foundational principles associated with CBD, and specific issues pertaining to cannabinoids in the food supply,” a notice for the October 17 forum, which will be led by NASEM’S Food and Nutrition Board, states.
While hemp and its derivatives were federally legalized under the 2018 Farm Bill, the Food and Drug Administration (FDA) has yet to issue regulations for CBD products that would allow for their lawfully marketing as food items or dietary supplements. That’s created tension within Congress, with multiple lawmakers from both sides of the aisle stressing that the intent of Congress in passing the agriculture legislation was to ensure that these products could be sold.
A recent letter to FDA, signed by 26 lawmakers, stated that “FDA’s current regulatory posture on CBD has created significant regulatory and legal uncertainty for participants in this quickly evolving industry.”
Senate Majority Leader Mitch McConnell (R-KY), who championed the hemp legalization provision of the Farm Bill, also pushed FDA to speed up the rulemaking process for CBD businesses.
No FDA officials are listed as taking part in NASEM’s event, though Renée Johnson of the Congressional Research Service will participate.
— National Academy of Medicine (@theNAMedicine) September 12, 2019
Johnson will be joined by Roger Clemens of the University of California School of Pharmacy and Daniele Piomelli, who serves as director of the Institute for the Study of Cannabis at the University of California at Irvine.